Understanding Prostate Cancer with Specific Gene Changes
Androgen Signaling in CaP with loss of MAP3K7 and CHD1
['FUNDING_R01'] · UNIVERSITY OF COLORADO DENVER · NIH-11121756
This project explores how certain gene changes make prostate cancer more aggressive and resistant to treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-11121756 on ClinicalTrials.gov |
What this research studies
Prostate cancer often involves large changes in its genetic material. This project focuses on two specific genes, CHD1 and MAP3K7, which are frequently missing together in a particular type of aggressive prostate cancer. Researchers are using advanced models to understand how the loss of these genes makes prostate cancer more aggressive, changes how cells grow, and affects their response to hormone therapy. They are also studying human prostate cancer cells to see how these gene losses lead to resistance to common treatments. The ultimate goal is to find new ways to identify and target this aggressive form of prostate cancer.
Who could benefit from this research
Good fit: This research focuses on prostate cancer patients whose tumors have specific deletions in the CHD1 and MAP3K7 genes.
Not a fit: Patients whose prostate cancer does not involve these specific gene deletions may not directly benefit from this particular line of research.
Why it matters
Potential benefit: This work could lead to new ways to identify and treat aggressive prostate cancer, especially for patients with these specific gene changes.
How similar studies have performed: While initial findings suggest a functional link between these gene changes and aggressive prostate cancer, this project aims to uncover new therapeutic targets, building on existing knowledge.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CRAMER, SCOTT D — UNIVERSITY OF COLORADO DENVER
- Study coordinator: CRAMER, SCOTT D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.